Oncology & Cancer

Sickle cells show potential to attack aggressive cancer tumors

By harnessing the very qualities that make sickle cell disease a lethal blood disorder, a research team led by Duke Medicine and Jenomic, a private cancer research company in Carmel, Calif., has developed a way to deploy ...

Oncology & Cancer

Study suggests gene variation may shape bladder cancer treatment

(Medical Xpress)—Patients who have inherited a specific common genetic variant develop bladder cancer tumors that strongly express a protein known as prostate stem cell antigen (PSCA), which is also expressed in many pancreatic ...

Medications

FDA OKs expanded use of prostate cancer drug

(HealthDay)—The approved use of the drug Zytiga has been expanded to include treatment of men with late-stage, hormone therapy-resistant prostate cancer before they undergo chemotherapy, the U.S. Food and Drug Administration ...

Oncology & Cancer

Clinical trial targets advanced prostate cancer

Select patients with advanced prostate cancer may benefit from a Georgia Health Sciences University Cancer Center clinical trial that looks to improve survival rates of the FDA-approved prostate cancer drug Provenge.

Oncology & Cancer

COUP-TFII sparks prostate cancer progression

Prostate cancer presents a dilemma for patients and the physicians who treat them. Which cancers are essentially indolent and present no risk and which are life threatening? Which can be watched and which need aggressive ...

page 30 from 40